Comparative Pharmacology
Head-to-head clinical analysis: BRISTAGEN versus ZINC BACITRACIN NEOMYCIN SULFATE POLYMYXIN B SULFATE HYDROCORTISONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRISTAGEN versus ZINC BACITRACIN NEOMYCIN SULFATE POLYMYXIN B SULFATE HYDROCORTISONE.
BRISTAGEN vs ZINC BACITRACIN,NEOMYCIN SULFATE,POLYMYXIN B SULFATE & HYDROCORTISONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bristagen (amikacin) is an aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis.
Combination antibiotic and corticosteroid: Neomycin, polymyxin B, and bacitracin are antibiotics that inhibit bacterial protein synthesis, disrupt cell membrane permeability, and inhibit cell wall synthesis, respectively; hydrocortisone is a corticosteroid that suppresses inflammatory responses by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.
1-2 mg/kg IM or IV every 8-12 hours; typical adult dose is 1 mg/kg every 8 hours.
Apply 3-4 times daily to affected area as a thin layer. Topical route. Frequency: every 6-12 hours.
None Documented
None Documented
2.5 hours (prolonged to 20-40 hours in renal impairment).
Neomycin: 2-3h (systemic, IM); Bacitracin: 1.5h (systemic, IM); Polymyxin B: 6h (systemic, IV); Hydrocortisone: 1.5-2h (systemic). Topical: not applicable due to minimal absorption.
Renal (90% unchanged via glomerular filtration); biliary/fecal excretion <10%.
Renal: Neomycin (<1% absorbed, remainder fecal), Bacitracin (10-40% renal if absorbed, negligible), Polymyxin B (60% renal over 24h if absorbed), Hydrocortisone (metabolized, <1% unchanged renal; fecal for unabsorbed). Topical: negligible systemic absorption; fecal for unabsorbed.
Category C
Category A/B
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic